bioRxiv Science⌕ Search

Biology subjects

Maniar, K. K.

Publications and source records attributed to Maniar, K. K..

2 recordsLinked to original sources

A Vascularized Liver Microphysiological System Captures Key Features of Hepatic Insulin Resistance and Monocyte Infiltration

Three-dimensional in vitro liver models are a promising means to recapitulate key aspects of human liver disease pathologies, thereby aiding therapeutic development. Spheroidal aggregates of hepatocytes, sometimes including non-parenchymal cells, are an established approach for modeling facets of metabolism and drug responses, yet these models often lack dynamic interactions with vascular and immune cells that also contribute to disease development and progression. To address this, we developed a microphysiological system (MPS) that integrates multicellular human hepatic spheroids with self-organized microvascular networks. We show extensive interaction between primary human spheroids and functional vasculature while maintaining key hepatic functions. We demonstrate the utility of this MPS by modeling an insulin resistance state through chronic exposure to disease-mimetic media conditions. This disease model displays altered hepatocyte metabolism, dysregulated vascular features, and increased inflammation state. Enabled by the functional vasculature, we further extend this disease model to capture changes in immune cell recruitment. When culturing CD14+ monocytes in our liver MPS, a subset of monocytes extravasate, localize to hepatic spheroids, and begin differentiating into CD163+ macrophages. These cells infiltrate with greater frequency in insulin resistant samples, consistent with known clinical findings. All together, this vascularized MPS model captures disease-relevant liver biology including inflammatory features.

bioengineering↗

Qualifying a human Liver-Chip for predictive toxicology: Performance assessment and economic implications

Human organ-on-a-chip (Organ-Chip) technology has the potential to disrupt preclinical drug discovery and improve success in drug development pipelines as it can recapitulate organ-level pathophysiology and clinical responses. The Innovation and Quality (IQ) consortium formed by multiple pharmaceutical and biotechnology companies to confront this challenge has published guidelines that define criteria for qualifying preclinical models, however, systematic and quantitative evaluation of the predictive value of Organ-Chips has not yet been reported. Here, 870 Liver-Chips were analyzed to determine their ability to predict drug-induced liver injury (DILI) caused by small molecules identified as benchmarks by the IQ consortium. The Liver-Chip met the qualification guidelines across a blinded set of 27 known hepatotoxic and non-toxic drugs with a sensitivity of 87% and a specificity of 100%. A computational economic value analysis suggests that with this performance the Liver-Chip could generate $3 billion annually for the pharmaceutical industry due to increased R&D productivity.

pharmacology and toxicology↗